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thought that it might be of considerable interest if we could reiterate these findings among our patient population.
Methods

Study design
Forty consecutive patients referred for a clinically indicated DSE were prospectively enrolled in this observational case-control study from June 2018 to January 2019. Another 40 consecutive patients who underwent standard DSE during the past 6 months served as controls. Clinical indications for DSE were the evaluation of angina pectoris in patients with intermediate pretest probability for CAD, evaluation of patients with atypical chest pain, and for those with uninterpretable electrocardiograms (ECGs) at baseline. Exclusion criteria were a recent myocardial infarction (within 3 days), unstable angina, recent ventricular tachycardia, atrial fibrillation with the rapid ventricular response, severe hypertension, and significant aortic stenosis. Concurrent medications were continued at the discretion of the referring physician. The study was approved by our local ethical committee and written informed consents were obtained from all patients.
Dobutamine stress echocardiographic procedure
B a s e l i n e t w o -d i m e n s i o n a l ( 2 -D ) t r a n s t h o r a c i c echocardiographic examination (Philips EPIQ 7 Ultrasound System, Andover, MA, USA) was performed in the standard views (parasternal long-and short-axis, apical 2-and 4-chamber views), and a 12-lead ECG at rest was obtained.
Standard dobutamine-atropine infusion protocol
Dobutamine was infused with 3-min dose increments, starting from 5 µg/kg/min and increasing to 10, 20, 30, 40, and 50 µg/kg/min. The ECG was monitored throughout dobutamine infusion and recorded each minute. Cuff blood pressure (BP) was measured at rest, every 3 min during stress, and at maximal stress. When no endpoint was reached, atropine (0.5-1.0 mg) was given to the continuing 40 µg/kg/min dobutamine infusion stage if no contraindications such as glaucoma or prostatic enlargement were present. The infusion was terminated after the maximal dose was reached or at 1 of the following end points: • More than 85% of the age-predicted maximal HR • A decrease in BP of >40 mm Hg from the resting value or a systolic BP (SBP) of <90 mm Hg • The occurrence of severe hypertension (SBP of >240 mm Hg or diastolic BP of >120 mm Hg) • Significant cardiac arrhythmias • Severe chest pain • Horizontal or downsloping ECG ST depression of ≥1 mm measured 80 ms after the J point or ST-segment elevation ≥1 mm in the absence of Q waves • Marked new echocardiographic regional wall motion abnormalities in multiple locations • Severe vagal reactions or other intolerable noncardiac symptoms.
Metoprolol was available and was administered intravenously (2.5-5 mg) to reverse the effects of dobutamine if these did not revert spontaneously or rapidly.
Accelerated protocol
Dobutamine was administered at a constant dose of 50 µg/kg/min for up to 10 min. Early echocardiographic images were obtained starting at 20 s (roughly corresponding to the cumulative dose given over 3 min at 5 µg/kg/min). When no endpoint was reached, atropine (0.5 or 1.0 mg) was given to the continuing 50 µg/kg/min dobutamine infusion at 5 min into the study in the absence of contraindications, and repeated to a maximum of 1.0 mg, if necessary. Dobutamine infusion was discontinued after 10 min or for 1 of the endpoints mentioned above.
Images interpretation
Off-line assessment of echocardiographic images was performed by an investigator who was blinded to clinical information, ECG findings, and study protocol. Regional wall motion was assessed according to the recommendations of the American Society of Echocardiography using a 17-segment model, [13] and wall motion was graded as follows: 1 = normal, 2 = hypokinetic, 3 = akinetic, and 4 = dyskinetic. [13] The test was considered positive when wall motion in any segment deteriorated >1 grade, except for a change from resting akinesia to dyskinesia. [14] Studies were identified as nondiagnostic if the patient reached 85% age-predicted maximal HR in the absence of inducible ischemia. For each individual patient, 2-D echocardiographic images were recorded at baseline, low dose, peak stress, and during recovery. Images of 4 standard imaging planes were digitized and displayed in a standard quad-screen digital format that allowed offline side by side comparison.
Statistical analysis
Data management and statistical analysis were done using SPSS version 25. (IBM, Armonk, New York, United states). Numerical data were summarized as means and standard deviations. Categorical data were summarized as numbers and percentages. Before running comparisons, numerical data were assessed for normality using normality tests and direct visualization methods. Comparisons between two groups were done using independent t-test for numerical variables. In comparisons limited only for patients using β-Blockers; Mann-Whitney U-test (nonparametric test) was used due to relatively small numbers in both groups. Categorical data were compared using the Chi-square test or Fisher's exact test if appropriate. All P values were two-sided. Values of P < 0.05 were considered statistically significant.
results
Baseline characteristics
The study participants consisted of 80 patients (43 males, mean age 56 ± 10 years). All patients had limited exercise capacity and intermediate pre-test probability [15] for CAD. They were referred for a clinically indicated DSE to evaluate anginal symptoms. Forty patients underwent accelerated protocol for DSE, and 40 patients underwent the standard protocol. Among the whole study population, 58 patients had angina pectoris, 14 patients had atypical chest pain, and 8 patients had uninterpretable ECG at baseline. There were no statistically significant differences between both groups regarding various baseline criteria [ Table 1 ].
Hemodynamic data
No statistically significant differences were seen between both groups regarding baseline HR (74 ± 9 vs. 74 ± 11 bpm, P = 0.991 for accelerated and standard groups, respectively) and baseline SBP (119 ± 10 vs. 121 ± 10 mmHg, P = 0.355 for accelerated and standard groups, respectively). Patients in the accelerated protocol achieved a significantly more rapid increase in HR compared to those in the standard protocol (11.5 ± 2.3 vs. 5.3 ± 1.3 bpm, respectively, P < 0.001). Peak HR, peak SBP, and percent of patients achieving target HR were similar between both groups [ Table 2 ].
Echocardiographic data
There were no statistically significant differences between both groups regarding wall motion score index, left ventricular end-diastolic volume, left ventricular end-systolic volume , and left ventricular ejection fraction (LVEF) both at rest and at peak stress [ Table 3 ].
Test parameters
Patients who underwent the accelerated protocol had a significantly shorter stress times compared to those who underwent the standard protocol (6 ± 2 vs. 14 ± 3 min respectively, P < 0.001) [ Figure 1a ]. Moreover, the total cumulative dobutamine dose was significantly lesser in the group of the accelerated protocol (275 ± 63 vs. 355 ± 144 µg/kg, P = 0.029) [ Figure 1b ]. There was no statistically significant difference between accelerated and standard protocol groups in the frequency of atropine use (12.5 vs. 10%, respectively, P = 1) nor in the final test results (positive in 35 vs. 37.5%, respectively, P = 0.816) with others being negative. No tests were reported to be nonconclusive.
Effect of β-blockers
Among patients who did not stop β-blockers before the test (31 patients), differences observed between accelerated and standard protocols for the entire population were also maintained. This included a significantly shorter stress time, lesser total cumulative dobutamine dose, and a more rapid HR increase. Again, with similar peak SBP, peak HR, percent achieving target HR, and percent use of atropine [ Table 4 ].
Test tolerability
No major complications occurred in either group. There were no statistically significant differences between accelerated and standard protocol groups regarding occurrence of both arrhythmic side effects (30% vs. 32.5%, P = 0.809) and nonarrhythmic side effects (27.5 vs. 30%, P = 0.805). Table 5 shows the frequency of adverse effects and arrhythmias induced in both DSE protocols. The most frequent nonarrhythmic side effect was hypotension, which occurred in six patients and warranted termination of the test in only 1 patient. All arrhythmic episodes were asymptomatic and did not warrant test termination in any patient.
dIscussIon
In the present study, a single, high, and continuous infusion of dobutamine for stress induction in DSE appears as safe and effective as the standard protocol. This finding reaffirms other few previous studies examining the issue [7] [8] [9] [10] [11] [12] and adds to the accumulating body of evidence supporting the use of the accelerated DSE protocol.
Similar to Burger et al. [8] and Minardi et al., [11] we showed that the accelerated protocol resulted in a more rapid increase in HR, which enabled patients to achieve their target HR rapidly resulting in significantly shorter stress time and lower total cumulative dobutamine dose compared to the standard protocol.
The fact that the accelerated DSE protocol resulted in a shorter stress time without sacrificing safety makes sense. It implies that this protocol could be of value for some very busy laboratories with a high volume of patients referred for the assessment of CAD. However, we do not recommend the universal use of such a protocol for all patients. Cardiologists should still employ an individualized approach in test selection.
Interestingly, we demonstrated that differences between both protocols in terms of shorter stress times and lower cumulative dobutamine dose were maintained among the subgroup of patients whose physicians preferred not to stop β-blockers before the test. This gives more validity to the accelerated DSE protocol and indicates that it could be applied to a wide spectrum of patients, considering that withholding β-blockers before DSE is not always possible for all patients.
Because dobutamine in the accelerated protocol is administered in a single, high, and continuous fashion (without increments), a major concern is a potential rise in arrhythmic and ischemic adverse effects. Nevertheless, we did not find any significant increase in either arrhythmic or nonarrhythmic complications between both protocols. The explanation why the accelerated protocol did not result in a significantly higher incidence of arrhythmic complications is difficult, but we speculate that the lower total cumulative dobutamine dose could be the key player here (in light of the normal mean LVEF of the included patients). Actually, there are data from the literature supporting this theory; with some investigators suggesting that dobutamine triggers arrhythmia only in the presence of an ischemic substrate, [15] and others demonstrating the occurrence of serious ventricular arrhythmias in doses of dobutamine as low as 20 µg/kg/min or even after cessation of infusion! [16] Of note, no patients in the accelerated group developed anginal pain (as a complication of the test), in contrast to three patients only in the standard group. This was unexpected given the limited exercise capacity as described in the baseline criteria of the included patients. Nevertheless, we think that this may be a play of chance due to the small sample size in the current study.
The current study is not without limitations. First, small sample size and the single-center experience lack the power to detect differences in uncommon side effects. Second, the diagnostic accuracy of DSE for detection of the presence of CAD was not evaluated in the present study, as this would require a much larger sample size and a large-scale multicenter design to determine both sensitivity and specificity. Third, although echocardiographic images in the current study were obtained starting at 20 s (which roughly corresponds to a low dose dobutamine of 5 µg/kg/min) and thus might be advocated for "viability" assessment, we should state that this work was not designed primarily to test this hypothesis. A separate standard low dose of dobutamine (5 µg/kg/min) should be employed if the evaluation of viability is clinically needed.
conclusIon
The accelerated protocol of DSE consisting of infusion of a single, high, and continuous dose of dobutamine is as safe and effective as the standard one. It resulted in significantly shorter stress times and lower total cumulative dobutamine dose, which might translate into a more rapid patient turnover in busy laboratories. Further large-scale studies are needed to test the diagnostic accuracy of such a protocol.
